XH001 Combination With Ipilimumab and Chemotherapy for Patients With Resected Pancreatic Cancer - Trial NCT06353646
Access comprehensive clinical trial information for NCT06353646 through Pure Global AI's free database. This phase not specified trial is sponsored by Wu Wenming and is currently Not yet recruiting. The study focuses on Pancreatic Cancer. Target enrollment is 12 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Wu Wenming
Peking Union Medical College Hospital
Timeline & Enrollment
N/A
Apr 01, 2024
Dec 01, 2026
Primary Outcome
DFS,1-year DFS rate,MFS,OS
Summary
This is a single-center, open label, single-arm, investigator-initiated study to evaluate the
 efficacy and safety of XH001 (neoantigen cancer vaccine) sequential combination with
 ipilimumab and chemotherapy in pancreatic cancer patients following surgical resection.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06353646
Non-Device Trial